GenSight Biologics S.A.
Develops gene therapies for neurodegenerative retinal and central nervous system diseases.
SIGHT | PA
Overview
Corporate Details
- ISIN(s):
- FR0013183985 (+3 more)
- LEI:
- 549300NK4AB8OUEX1F54
- Country:
- France
- Address:
- 74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
- Sector:
- Manufacturing
Description
GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-03-07 15:09 |
Franchissement de seuils
|
French | 21.3 KB | ||
| 2019-03-07 15:09 |
Franchissement de seuils et déclaration d'intention
|
French | 27.1 KB | ||
| 2019-03-04 19:02 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 39.2 KB | ||
| 2019-02-25 19:16 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 79.5 KB | ||
| 2019-02-25 19:16 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 69.4 KB | ||
| 2019-02-12 18:30 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 39.2 KB | ||
| 2019-02-12 07:30 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 35.6 KB | ||
| 2019-02-12 07:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 35.6 KB | ||
| 2019-01-23 07:30 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 29.4 KB | ||
| 2019-01-23 07:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 29.4 KB | ||
| 2019-01-23 07:30 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 28.4 KB | ||
| 2019-01-23 07:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 27.9 KB | ||
| 2019-01-15 17:45 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 39.2 KB | ||
| 2019-01-15 17:45 |
Rachat d'actions / Contrat de liquidité Information relative au contrat de liqu…
|
French | 31.3 KB | ||
| 2018-12-12 07:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 72.0 KB |
Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GenSight Biologics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-09 | N/A | Other | Other | 5,063,291 | 1,999,999.95 EUR |
| 2024-02-07 | N/A | Other | Other | 5,224,660 | 1,999,999.85 EUR |
| 2023-11-21 | N/A | Other | Other | 3,038,279 | 2,163,862.30 EUR |
Peer Companies
